Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL (Ph+ ALL-2026)
A Prospective, Umbrella, Phase 2 Study of Immunotargeted Agents Combined With Low-Dose Chemotherapy in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive B-Cell Acute Lymphoblastic Leukemia
This is a prospective, open-label, single-arm, umbrella phase 2 clinical trial enrolling 22 adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) B-cell acute lymphoblastic leukemia (ALL).
As an umbrella trial, all patients share the same target disease (newly diagnosed Ph+ B-ALL) and receive a uniform induction backbone consisting of multi-targeted immunotherapy, targeted therapy, and reduced-intensity chemotherapy. After induction, patients are stratified and assigned to two distinct consolidation pathways based on clinical condition, performance status, resource availability, and patient preference:
Pathway A: Consolidation with CD19-directed CAR-T cell therapy to achieve deep molecular remission; Pathway B: Consolidation with sequential immunochemotherapy to maximize minimal residual disease (MRD) clearance.
A backup chemotherapy backbone is provided for patients ineligible for antibody therapy. All patients, regardless of consolidation pathway, proceed to a unified long-term maintenance regimen. The primary endpoint is the complete molecular remission (CMR) rate after one cycle of induction therapy. MRD is monitored longitudinally by flow cytometry, quantitative PCR, and immune repertoire sequencing. Safety is evaluated per NCI CTCAE version 5.0.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
連絡先と場所
研究連絡先
研究連絡先
- 名前:Ying Wang, MD, PhD
- 電話番号:+86 22-23608095
- メール:wangying1@ihcams.ac.cn
研究場所
-
-
Tianjin Municipality
-
Tianjin、Tianjin Municipality、中国、301600
- Chinese Academy of Medical Sciences Hospital of Hematology (Chinese Academy of Medical Sciences Institute of Hematology)
-
コンタクト:
- Runxia Gu
- 電話番号:+86-22-23608095
- メール:gurunxia@ihcams.ac.cn
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age ≥ 18 years
- Newly diagnosed, previously untreated Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL) confirmed by cytogenetics and/or molecular testing
- Leukemic blasts expressing CD22
- Adequate organ function (renal, hepatic, cardiac)
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- Life expectancy ≥ 3 months
- Written informed consent obtained prior to any study-related procedures
Exclusion Criteria:
- Prior systemic anti-leukemic therapy, including chemotherapy, targeted therapy, or immunotherapy
- History of chronic myeloid leukemia (CML) or other hematologic malignancies
- Central nervous system (CNS) leukemia or extramedullary disease at diagnosis
- Uncontrolled active infection or severe comorbidities
- HIV positivity or known hepatitis B/C infection with active viral replication
- Pregnant or breastfeeding
- Inability to comply with study procedures or follow-up requirements
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Immunotargeted Therapy + Low-Dose Chemotherapy Arm
All patients receive a uniform induction therapy backbone combining targeted therapy, immunotherapy, and reduced-intensity chemotherapy. After induction, patients are stratified into two consolidation pathways based on clinical status: 1) CD19 CAR-T cell therapy; 2) sequential immunochemotherapy. All patients proceed to a unified long-term maintenance regimen. |
Third-generation tyrosine kinase inhibitor (TKI) targeting BCR::ABL1, administered orally daily as part of induction, consolidation, and maintenance therapy. BCL-2 inhibitor administered orally daily during induction and consolidation cycles to enhance leukemic cell apoptosis. Anti-CD22 antibody-drug conjugate (ADC) administered intravenously during induction and consolidation therapy. CD19/CD3 bispecific T-cell engager (BiTE) administered as continuous intravenous infusion during consolidation therapy. Autologous CD19 CAR-T cell therapy administered as a single intravenous infusion as optional consolidation therapy for eligible patients. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Complete Molecular Remission (CMR) Rate After 1 Cycle of Induction Therapy
時間枠:At the end of Cycle 1 (each cycle is 28 days, approximately 4 weeks from enrollment)
|
The proportion of patients achieving complete molecular remission (CMR), defined as undetectable BCR::ABL1 transcript by quantitative PCR (BCR::ABL1/ABL1 ratio < 0.001%), after 1 cycle of induction therapy. |
At the end of Cycle 1 (each cycle is 28 days, approximately 4 weeks from enrollment)
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
3-Month Complete Remission (CR)
時間枠:3 months after study enrollment
|
3 months after study enrollment
|
|
|
3-Month MRD Negativity Rates
時間枠:3 months after study enrollment
|
3 months after study enrollment
|
|
|
2-Year Overall Survival (OS)
時間枠:2 years after the last patient enrollment
|
OS is defined as the time from study enrollment to death from any cause. |
2 years after the last patient enrollment
|
|
2-Year Disease-Free Survival (DFS)
時間枠:2 years after the last patient enrollment
|
DFS is defined as the time from study enrollment to disease relapse or death from any cause. |
2 years after the last patient enrollment
|
|
2-Year Event-Free Survival (EFS)
時間枠:2 years after the last patient enrollment
|
EFS is defined as the time from study enrollment to first occurrence of predefined adverse events, disease progression or death. |
2 years after the last patient enrollment
|
|
Incidence of Treatment-Related Adverse Events (TRAEs)
時間枠:From study enrollment to 60 days after the last treatment
|
Number and severity of adverse events graded according to NCI CTCAE version 5.0. |
From study enrollment to 60 days after the last treatment
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- IIT2026061
- IIT2026061-EC-1 (その他の識別子:Ethics Committee of Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。